Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
BATON ROUGE, La., April 24, 2017 -- Amedisys, Inc. (NASDAQ:AMED), announced today that it will report results for the first quarter ended March 31, 2017 after the market closes on May 2, 2017. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on May 3, 2017.
To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (877) 524-8416 (Toll-Free) or (412) 902-1028 (Toll). A replay of the conference call will be available through June 3, 2017. The replay dial-in number is (877) 660-6853 (Toll-Free) or (201) 612-7415 (Toll) and reference conference ID #13660189.
A live webcast of the call will be accessible through our website on our Investor Relations section at the following web address: http://investors.amedisys.com.
About Amedisys:
Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 2,200 hospitals and 61,900 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 16,000 employees, in 421 care centers in 34 states, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 385,000 patients in need every year. For more information about the Company, please visit: www.amedisys.com.
We use our company website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding the Company is routinely posted on and accessible on the "Investor Relations" subpage of our website, which is accessible by clicking on the tab labeled "Investors" on our website home page. Visitors to our website can also register to receive automated e-mail and other notifications alerting them to when new information is made available on the Investor Relations subpage of our website. In addition, we make available on the Investor Relations subpage of our website (under the link "SEC filings") free of charge our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms 3, 4 and 5 and any amendments to those reports as soon as practicable after we electronically file such reports with the SEC. Further, copies of our Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct and the charters for the Audit, Compensation, Nominating and Corporate Governance, Quality of Care and Compliance and Ethics Committees of our Board are also available on the Investor Relations subpage of our website (under the link "Corporate Governance").
Contact: Amedisys, Inc. David Castille Managing Director, Finance and Assistant Treasurer 225.299.3665 [email protected]
